Happy with this Ann. I didn't see South Korea coming but it seems a sensible choice for a number of reasons they have outlined.
Frustrating that at 10.06 they announce a conference call taking place 24 minutes later. It's way too short notice. I dialed in late and heard Tom talking over the last couple of slides. He did then give an opportunity to ask questions via the operator but because the timeframe was so compressed I hadn't properly digested the Prezzo by that point. Why not do the call this afternoon and give people a chance to get their head around the details of the announcement?
Further derisked and clearly the Ann of the design & commencement of the P3 trial is the next key checkpoint. The biggest plus about this morning's Ann for me is that they have reduced the development stage by circa 12 mths by partnering with Peptron.
Still seems very much under the radar in the market. No volume. This company needs some / more publicity.
- Forums
- ASX - By Stock
- IXC
- Ann: Notice of Investor Call and Presentation
IXC
invex therapeutics ltd
Add to My Watchlist
0.00%
!
9.1¢

Ann: Notice of Investor Call and Presentation, page-16
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.839M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 41290 | 8.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 9000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 41290 | 0.088 |
1 | 42086 | 0.083 |
1 | 40000 | 0.075 |
1 | 14285 | 0.070 |
1 | 16666 | 0.060 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 9000 | 1 |
0.099 | 59180 | 2 |
0.105 | 50000 | 1 |
0.150 | 713 | 1 |
0.000 | 0 | 0 |
Last trade - 16.21pm 04/07/2025 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online